Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: Comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside

Elihu H. Estey, Peter F. Thall, Francis J. Giles, Xue Mei Wang, Jorge E. Cortes, Miloslav Beran, Sherry A. Pierce, Deborah A. Thomas, Hagop M. Kantarjian

Research output: Contribution to journalArticlepeer-review

128 Scopus citations

Fingerprint

Dive into the research topics of 'Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: Comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds